Cite
MLA Citation
C.C. Lin et al.. “Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC).” European journal of cancer, vol. 138, n.d., pp. S12–S13. http://access.bl.uk/ark:/81055/vdc_100120043768.0x000028